Page contentsPage contents Key facts Decision Key facts Active substance cetrelimab Therapeutic area Neoplasms benign, malignant and unspecified (incl cysts and polyps) Decision number EMA/PE/0000230610 PIP number EMA/PE/0000230610 Pharmaceutical form(s) All pharmaceutical forms Condition(s) / indication(s) Treatment of malignant bladder neoplasms Route(s) of administration All routes of administration Contact for public enquiries Janssen Cilag International Email: contact@Janssen-emea.com Tel. +32 14602111 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 16/04/2025 Compliance check done No Decision EMA/PE/0000230610 : EMA decision of 16 April 2025 on the granting of a product specific waiver for cetrelimabAdopted Reference Number: EMADOC-1700519818-2036387 English (EN) (240.42 KB - PDF)First published: 03/07/2026 View Share this page